Factors associated with progression of depression, anxiety, and stress‐related symptoms in outpatients and inpatients with COVID‐19: A longitudinal study. Issue 4 (20th May 2022)

• Record Type: Journal Article
• Authors: Hoşgören Alıcı, Yasemin; Çınar, Güle; Hasanlı, Jamal; Ceran, Selvi; Onar, Deha; Gülten, Ezgi; Akdemir Kalkan, İrem; Memikoğlu, Kemal Osman; Çelik, Çaşit Olgun; Devrimci‐Ozguven, Halise
• Is Part Of: PsyCh Journal. Volume 11:Issue 4(2022)
• Page Start: 550
• Page End: 559
• Publication Date: 2022-05-20
• Subjects: anxiety -- COVID‐19 -- depression -- mental health -- psychopathology; Psychology -- Periodicals; 150
• DOI: 10.1002/pchj.557
• Languages: English
• ISSNs: 2046-0252

Abstract

Abstract: It is known that there is an increase in the frequency of psychiatric disturbances in the acute and post‐illness phase of coronavirus disease (COVID‐19). Comorbid psychiatric symptoms complicate the management of patients and negatively affect the prognosis, but there is no clear evidence of their progress. We aimed to determine psychiatric comorbidity in inpatients and outpatients with COVID‐19 and recognize the factors that predict psychiatric comorbidity. For this purpose, we evaluated patients on the first admission and after 4 weeks. We investigated psychiatric symptoms in outpatients ( n = 106) and inpatients ( n = 128) diagnosed with COVID‐19. In the first 7 days after diagnosis (first phase), sociodemographic and clinic data were collected, a symptom checklist was constructed, and the Hospital Anxiety and Depression Scale (HADS) and the Severity of Acute Stress Symptoms Scale (SASSS) were applied. After 30–35 days following the diagnosis, the SASSS and the HADS were repeated. In the first phase, the frequency of depression and anxiety were 55% and 20% in inpatients, and 39% and 18% in outpatients, respectively. In the second phase, depression scores are significantly decreased in both groups whereas anxiety scores were decreased only in inpatients. The frequencies of patients reporting sleep and attention problems, irritability, and suicide ideas decreased after 1 month. Patients with loss of smell and taste exhibit higher anxiety and depression scores in both stages. Our results revealed that the rate of psychiatric symptoms in COVID‐19 patients improves within 1 month. Inpatients have a more significant decrease in both depression and anxiety frequency than do outpatients. The main factor affecting anxiety and depression was the treatment modality. Considering that all patients who were hospitalized were discharged at the end of the first month, this difference may be due to the elimination of the stress caused by hospitalization.